Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

LORAZEPAM 2 MG TABLET

LORAZEPAM
$0.0706per EA
DEA Schedule CIV

Strength

2 mg/1

Manufacturer

Aurolife Pharma LLC

NDC

13107008501

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

LORAZEPAM

Approval Type

Generic (ANDA)

FDA Application

ANDA203572

On Market Since

2/1/2021

Pharmacological Classes

Benzodiazepine
Benzodiazepines

Price History

1W

0.0%

1M

-0.1%

3M

-0.1%

6M

-7.1%

1Y

-3.6%

3Y

+4.6%

5Y

-2.0%

All

+44.8%

Generic Alternatives

1 alternative • Same active ingredient

LORAZEPAM 2 MG TABLET
Generic
13107008505•Aurolife Pharma LLC
$0.0706

Related Drugs

Same classification

CLONAZEPAM 0.5 MG TABLET
Generic
00093083201•Teva Pharmaceuticals USA Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
00093083205•Teva Pharmaceuticals USA Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
00904722761•Major Pharmaceuticals
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
16729013600•Accord Healthcare Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
16729013616•Accord Healthcare Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
43547040610•Solco Healthcare US LLC
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
43547040611•Solco Healthcare US LLC
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
43547040650•Solco Healthcare US LLC
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
50268017315•AvPAK
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
59651072201•Aurobindo Pharma Limited
$0.0200
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy